New Rules: Onshoring Pharma Production to Cut Tariffs

You might care about this because the US government is taking big steps to secure its pharmaceutical supply. On April 2, 2026, the President announced Proclamation 11020. This Proclamation said that relying on imported pharmaceuticals and their ingredients could harm the national security of the United States. To address this, it placed a 100 percent tax, called a tariff, on certain imported patented medicines and their components. This tariff will start on September 29, 2026. However, there's a way for companies to avoid this high tariff. The Proclamation allows the Department of Commerce to make special agreements with pharmaceutical companies. If a company agrees to move its manufacturing of these drugs and ingredients back to the United States, a process called 'onshoring', they can get a much lower tariff rate. Instead of 100 percent, their tariff could be reduced to just 20 percent. Even better, for companies that also make certain pricing agreements with the Department of Health and Human Services, the tariff can be zero until January 20, 2029. This notice from the Department of Commerce explains the exact steps companies need to follow to apply for these onshoring agreements. It details what information they must provide and what commitments they need to make about their investment and production in the US. Companies are asked to submit their applications by June 12, 2026. This is a crucial opportunity for pharmaceutical companies to adjust their operations and potentially save a lot of money on import taxes while supporting domestic manufacturing. What makes this particular action by the Department of Commerce interesting is its direct and strong approach to changing where medicines are made. The US government is using significant tariffs as a tool to encourage companies to move their production facilities to American soil. This is not just a gentle suggestion. The 100 percent tariff is a powerful incentive to onshore manufacturing. The notice outlines a clear pathway for companies to reduce this tariff. This shows a determined effort to build a more secure domestic supply chain for critical medications, especially patented ones. The policy also includes a unique incentive: companies can get a zero percent tariff if they also agree to Most Favored Nation deals with the Department of Health and Human Services. This part suggests a dual goal: not only to bring manufacturing home but also potentially to influence drug pricing. The government has also put strong oversight and enforcement rules in place. Companies must report on their progress regularly, and these reports can be audited. If a company provides false information or commits fraud, they could face the original high tariffs again, even retroactively, along with other penalties. This means the commitments made in these agreements are serious and will be closely monitored. This combination of strong incentives and strict enforcement makes this document a significant statement about the future of pharmaceutical manufacturing in the United States. People who would find this legal document most relevant include pharmaceutical companies that import patented drugs or their ingredients into the United States. This particularly applies to those whose products would be subject to the new 100 percent tariffs. Manufacturers of active pharmaceutical ingredients, or APIs, also need to pay close attention. Legal professionals specializing in trade law, import regulations, or Section 232 investigations would find the application process and requirements highly important for advising their clients. Business leaders and strategists in the pharmaceutical and healthcare industries will want to understand these new rules to plan their future investments and supply chain arrangements. Investors and market analysts tracking the pharmaceutical sector would see this as a key development that could impact company valuations and market dynamics. Government affairs departments within pharmaceutical firms will be keenly interested in the specifics of the application and approval process. Anyone involved in public health and national security discussions will also find this document important. It directly addresses concerns about drug supply chain resilience and dependence on foreign manufacturing for essential medicines. This notice is for anyone whose work touches on the production, import, or regulation of patented pharmaceuticals in the US.